Acelyrin EBIT

Acelyrin (SLRN) currently reports a EBIT of $-290M as of March 2025. That compares with $-330M in the prior-year period — up 11.8% year over year. That is below the sector sector average of $-63M. Use the charts on this page to explore Acelyrin's EBIT history and peer comparisons.

Acelyrin's EBIT increased from $-330M to $-290M — a 11.8% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Acelyrin's EBIT of $-290M is lower than the its sector sector average of $-63M. That is roughly 358.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Acelyrin reported $-290M in EBIT as of March 2025. That compares with $-330M in the prior-year period — up 11.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-290M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-63M. From there, open related valuation or income-statement pages for Acelyrin, and consider following SLRN for alerts when major investors trade the stock.